Protocol No. 27919: "A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson's Disease with motor fluc
- Simuni, Tatyana (PD/PI)
- Zadikoff, Cindy (Co-Investigator)
Project: Research project